Product Description
Mechanisms of Action: OX40 Agonist
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Hoffmann-La Roche
Company Location: BASEL SWITZERLAND V8
Company CEO: Severin Schwan
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Transitional Cell Carcinoma
Phase 1: Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| GO29674 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2019-11-22 |
48% |
| 2016-004165-58 | P2 |
Completed |
Transitional Cell Carcinoma |
2018-04-25 |
|
| GO39590 | P2 |
Terminated |
Transitional Cell Carcinoma |
2018-04-25 |
|
| GO29313 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2017-07-14 |
40% |